Isotechnika Pharma may have isolated a new drug to combat organ rejection. Lead drug candidate voclosporin could replace cyclosporine as the immunosuppressant of choice for organ transplant recipients and patients with autoimmune conditions. Studies indicate it is more effective and has fewer side effects than cyclosporine. Isotechnika is testing the drug for kidney transplant recipients and psoriasis. Minority shareholder Paladin Labs has signed on to develop and market the drug in certain markets. Its Isotechnika Diagnostics division sells "breathalyzer" tests to diagnose H. pylori infections, which cause chronic gastritis and ulcers.

Vaccination is one of the most effective methods of preventing infectious diseases. That’s why Janssen Vaccines is committed to developing first-in-class or best-in-class vaccines for some of the world’s most life- threatening infectious diseases such as Ebola, Respiratory Syncytial Virus (RSV), Human Immunodeficiency Virus (HIV), Extra-intestinal Pathogenic E. coli (ExPEC) and polio. Most of our pipeline products are based on two innovative technology platforms – PER.C6® and AdVac®. We partner with many of the world’s leading experts, academic and clinical institutions and other pharmaceutical companies for the development of vaccines.

Jazz Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Palo Alto, California. Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes products for neurology and psychiatry primarily in the United States. The company's marketed products include Xyrem for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy; and Luvox CR for obsessive compulsive disorder and social anxiety disorder. Its product candidate in Phase III clinical trials comprise JZP-6 for the treatment of fibromyalgia. The company's other product candidates in clinical development comprises JZP-8, an intranasal formulation of clonazepam for the treatment of recurrent acute repetitive seizures in epilepsy patients who continue to have seizures while on stable anti-epileptic regimens; JZP-4, a controlled release formulation of an anticonvulsant for the treatment of epilepsy and bipolar disorder; and JZP-7 for the treatment of restless legs syndrome.

Kalypsys is searching for new medicines, and has developed a zippy way to find them. Its ultra-high throughput automated epiK screening system can analyze more than one million cell-based assay wells a day and can run 24 hours a day seven days a week. With that kind of research capability, the company has developed its own bioinformatics software to enable researchers to quickly find and compare data points. Kalypsys is generous enough to market the system, under the Kalypsys Systems brand, to other pharmaceutical research facilities. Its own drug development pipeline includes compounds in early stages of development, targeting cancer, inflammatory diseases, pain, and metabolic diseases.

Kreatech Biotechnology company develops tools used by pharmaceutical companies and medical researchers to detect and label RNA, DNA, and proteins. Its labeling kits, DNA probes, and other products are used in applications such as drug development and the diagnosis of disease. The company's investors include 3i Group, Alafi Capital, and Life Sciences Partners. Kreatech has formed alliances with many pharmaceutical and instrumentation firms, including heavyweights such as GE Healthcare Bio-Sciences and PerkinElmer.

La Jolla Pharmaceutical Company was founded in 1989 and is based in San Diego, California. La Jolla Pharmaceutical aimed to eliminate diseases. The development-stage firm was working with Toleragens, proprietary therapies that block the abnormal antibody production associated with certain autoimmune disorders without suppressing the entire immune system. Its lead drug candidate was Riquent, a treatment for renal disease associated with lupus. The drug would have been one of the few new drugs for lupus, and was being considered as a treatment for other autoimmune disorders. However, the company ceased most of its operations after trials of Riquent failed in 2009. Adamis Pharmaceuticals has announced it intends to acquire La Jolla Pharmaceuticals.

Lab901 is not that college class you flunked. It's a company that develops and manufactures laboratory processing products to increase the efficiency of analytical laboratory testing used for DNA tests and other applications. Lab901's ScreenTape system is disposable a credit-card sized strip patterned with reagents used to process and analyze biological samples such as blood, DNA, and RNA. Lab901 was formed in 2001.

Labcyte Inc. company sells automated dispensing systems, plate assemblers, microplates, and labware supplies. Labcyte's products are built around a liquid management technology it calls Acoustic Droplet Ejection (ADE) which uses sound energy to move miniscule bits of liquid without any physical contact during transfer. ADE is useful where cross-contamination would compromise quality or data and it reduces the waste created by disposable liquid handling supplies. Labcyte's customers include pharmaceutical and biomedical research labs. The company has expanded distribution of its products into Europe and Asia.

Laureate Pharma's protein purification and other production processes are pure poetry in motion. The contract manufacturing organization (CMO) develops, manufactures, and packages products used by pharmaceutical and biopharmaceutical companies to make drugs and diagnostics. The company's biopharmaceutical division specializes in making monoclonal antibodies and provides protein production and purification. Laureate also provides product formulation, aseptic filling, and bulk processing. It has partnerships with EMD Chemicals and GTC Biotherapeutics to provide products for clinical trials. Investment firm Safeguard Scientifics has sold its majority stake in Laureate Pharma to Saints Capital.

Lectus Therapeutics Limited is a UK-based pharmaceutical company. Its mission is to build a development pipeline containing first-in-class ion channel therapeutics identified through the use of its proprietary proteomics technology for pain management and the treatment of urinary bladder disorders.Lectus, which began operations in the summer of 2003, exploits the power of its proprietary functional proteomics platform, LEPTICS® (Leveraged Enabling Proteomics Technology for Ion Channel Screening), and builds on its knowledge of ion channels and protein-protein interactions, to identify and develop next-generation ion channel modulators that offer desirable clinical profiles with commensurate economic advantages.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.